{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:59:28Z","timestamp":1789153168098,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40265-023-01912-6","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T07:02:10Z","timestamp":1687330930000},"page":"1053-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Concizumab: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1912_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221085202","author":"DP Hart","year":"2022","unstructured":"Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022. https:\/\/doi.org\/10.1177\/20406207221085202.","journal-title":"Ther Adv Hematol."},{"issue":"10274","key":"1912_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630\u201340.","journal-title":"Lancet"},{"issue":"Suppl 6","key":"1912_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"9","key":"1912_CR4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40265-018-0922-6","volume":"78","author":"P Chowdary","year":"2018","unstructured":"Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab. Drugs. 2018;78(9):881\u201390.","journal-title":"Drugs"},{"key":"1912_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/JBM.S242219","volume":"13","author":"S Pasca","year":"2022","unstructured":"Pasca S. Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient\u2019s perspectives. J Blood Med. 2022;13:191\u20139.","journal-title":"J Blood Med."},{"key":"1912_CR6","unstructured":"Novo Nordisk Canada Inc. Concizumab (Alhemo\u2122): Canadian product monograph. 2023. https:\/\/www.novonordisk.ca. Accessed 01 May 2023."},{"key":"1912_CR7","unstructured":"Novo Nordisk. Novo Nordisk annual report 2022. 2023. https:\/\/www.novonordisk.com. Accessed 01 May 2023."},{"issue":"1","key":"1912_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","volume":"5","author":"AD Shapiro","year":"2021","unstructured":"Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279.","journal-title":"Blood Adv"},{"issue":"4","key":"1912_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1056\/NEJMe2216176","volume":"388","author":"C Leissinger","year":"2023","unstructured":"Leissinger C. Another victory for patients with hemophilia. N Engl J Med. 2023;388(4):372\u20133.","journal-title":"N Engl J Med"},{"key":"1912_CR10","unstructured":"Novo Nordisk. Health Canada approves Alhemo\u2122, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors [media release]. 17 April 2023. https:\/\/www.novonordisk.ca."},{"key":"1912_CR11","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation by the CHMP. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/medicines-human-use-under-evaluation. Accessed 18 May 2023."},{"issue":"24","key":"1912_CR12","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","volume":"119","author":"I Hilden","year":"2012","unstructured":"Hilden I, Lauritzen B, S\u00f8rensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871\u20138.","journal-title":"Blood"},{"issue":"6","key":"1912_CR13","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1111\/hae.13861","volume":"25","author":"B Lauritzen","year":"2019","unstructured":"Lauritzen B, Hilden I. Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: results from a rabbit haemophilia bleeding model. Haemophilia. 2019;25(6):e379\u201382.","journal-title":"Haemophilia"},{"issue":"11","key":"1912_CR14","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/jth.14272","volume":"16","author":"H Eichler","year":"2018","unstructured":"Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184\u201395.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1912_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/jth.15323","volume":"19","author":"M Kjalke","year":"2021","unstructured":"Kjalke M, Kjelgaard-Hansen M, Andersen S, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in vitro and ex vivo analyses. J Thromb Haemost. 2021;19(7):1687\u201396.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1912_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jth.14380","volume":"17","author":"B Lauritzen","year":"2019","unstructured":"Lauritzen B, Olling J, Abel KL, et al. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost. 2019;17(3):460\u20139.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1912_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jth.12864","volume":"13","author":"P Chowdary","year":"2015","unstructured":"Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743\u201354.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"1912_CR18","volume":"6","author":"V Jimenez Yuste","year":"2022","unstructured":"Jimenez Yuste V, Angchaisuksiri P, Castaman G, et al. Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer7 trial [abstract no. LB 01.2]. Res Pract Thromb Haemost. 2022;6(Suppl 1): e12787.","journal-title":"Res Pract Thromb Haemost."},{"key":"1912_CR19","unstructured":"Novo Nordisk. Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors [media release]. 10 July 2022. https:\/\/www.globenewswire.com\/."},{"issue":"Suppl 1","key":"1912_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2022-166522","volume":"140","author":"M Frei-Jones","year":"2022","unstructured":"Frei-Jones M, Cepo K, d\u2019Oiron R, et al. Subcutaneous concizumab prophylaxis in patients with hemophilia A or B with inhibitors: efficacy and safety results by hemophilia subtype from the phase 3 explorer7 trial [abstract no. 191]. Blood. 2022;140(Suppl 1):466\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1912_CR21","first-page":"E118","volume":"98","author":"AP Wheeler","year":"2023","unstructured":"Wheeler AP, Shapiro A, Porstmann T, et al. Risk mitigation during concizumab prophylaxis in phase 3 clinical trials in patients with hemophilia A\/B with and without inhibitors: management of breakthrough bleeds and dose optimization [abstract]. Am J Hematol. 2023;98(Suppl 1):E118\u20139.","journal-title":"Am J Hematol"},{"issue":"22","key":"1912_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood.2019001542","volume":"134","author":"AD Shapiro","year":"2019","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973\u201382.","journal-title":"Blood"},{"issue":"11","key":"1912_CR23","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","volume":"6","author":"AD Shapiro","year":"2022","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv. 2022;6(11):3422\u201332.","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.1007\/s40265-023-01924-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:22:29Z","timestamp":1691043749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01912-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"21 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01924-2","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01924-2","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}